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Abstract
Background: We have compared mutation analysis by DNA sequencing and Amplification Refractory Mutation
System™ (ARMS™) for their ability to detect mutations in clinical biopsy specimens.
Methods: We have evaluated five real-time ARMS assays: BRAF 1799T>A, [this includes V600E and V600K] and
NRAS 182A>G [Q61R] and 181C>A [Q61K] in melanoma, EGFR 2573T>G [L858R], 2235-2249del15 [E746-A750del] in
non-small-cell lung cancer, and compared the results to DNA sequencing of the mutation ‘hot-spots’ in these
genes in formalin-fixed paraffin-embedded tumour (FF-PET) DNA.
Results: The ARMS assays maximised the number of samples that could be analysed when both the quality and
quantity of DNA was low, and improved both the sensitivity and speed of analysis compared with sequencing.
ARMS was more robust with fewer reaction failures compared with sequencing and was more sensitive as it was
able to detect functional mutations that were not detected by DNA sequencing. DNA sequencing was able to
detect a small number of lower frequency recurrent mutations across the exons screened that were not
interrogated using the specific ARMS assays in these studies.
Conclusions: ARMS was more sensitive and robust at detecting defined somatic mutations than DNA sequencing
on clinical samples where the predominant sample type was FF-PET.
Introduction
The molecular analysis of tumours has become increas-
ingly important in recent years, particularly to aid the
choice of drug therapy [1,2]. Assays to evaluate clinical
samples, particularly if the results are used to determine
treatment regimens, need to be rapid, precise and speci-
fic. However, the processes used to prepare tumours for
standard pathology analysis for diagnosis, while preser-
ving the tissue architecture, have a detrimental effect on
DNA and RNA. Formalin fixation and subsequent
embedding in paraffin tends to fragment and cause
adducts in the DNA that can make analysis challenging
[3]. In addition, tumour specimens are heterogeneous.
They can contain surrounding and infiltrating normal
cells, and not all tumour cells are identical. Analysis
methods must therefore also be sensitive.
DNA sequencing is one of the most widely used meth-
ods for analysing DNA and has been successfully used to
analyse and detect mutations in DNA derived from for-
malin-fixed paraffin-embedded tumours (FF-PETs) for
many years. It is a well-established method, widely avail-
able and relatively inexpensive to use [4,5] and can detect
any mutation in the sequence being analysed. DNA
sequencing is often quoted as the ‘gold standard’ for
DNA sequence analysis [6]. However, sequencing is not
exquisitely sensitive. A mutation must be present in
approximately 20% of the sample to be readily detected
[7,8]. Studies in colorectal cancer have found the percen-
tage mutation in a tumour sample to be as low as 6%,
significantly lower than sequencing is able to detect [9].
Given the heterogeneity of tumours [10] the percentage
is possibly even lower in some tumour biopsy specimens.
We have extensive experience in the development and
use of the allele specific polymerase chain reaction
(PCR)-based method ARMS™ (Amplification Refractory
Mutation System) [11]. These assays are sensitive, routi-
nely being able to detect at least 1% mutant in a normal
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PCR-based method can be further enhanced by the abil-
ity to analyse the results in a real-time, closed-tube
format by incorporating fluorescent probes such as
TaqMan [12], Scorpions [13], Molecular Beacons [14] or
intercalating fluorescent dyes such as Yo-Pro [15] or
Sybr green [16], which eliminates PCR product contami-
nation and reduces the time to generate results. They
p e r f o r mw e l lo nF F - P E T - d e r i v e dD N Aa n dt h e i rs e n s i -
tivity makes them ideal for the analysis of heterogeneous
tumour samples. Unlike sequencing, ARMS assays only
detect the mutations they were designed to interrogate.
However, this could be considered an advantage in a
clinical setting so that decisions on treatment or
patient-outcome results are based only on known, clini-
cally validated mutations.
We have evaluated three real-time ARMS assays
in melanoma tumour samples: BRAF 1799T>A [this
includes V600E and V600K], NRAS 182A>G [Q61R]
and 181C>A [Q61K], and two real-time ARMS assays in
non-small-cell lung cancer (NSCLC) samples: EGFR
2573T>G [L858R] and 2235-2249del15 [E746-A750del],
for the analyses FF-PET DNA and compared the results
to DNA sequencing of the exons containing mutation
hot-spots for these genes (BRAF exon 15, NRAS exon 1,
EGFR exons 18-21). The data presented in this paper
will demonstrate that ARMS is superior to sequencing
in both sensitivity and robustness on a large and diverse
set of clinical tumour samples making ARMS a suitable
choice for the analysis of known, well-characterised
mutations such as those found in RAS, BRAF and EGFR
compared to DNA sequencing.
Methods
Samples
Unresectable American Joint Committee on Cancer
Stage 3 or 4 malignant melanoma samples were
obtained as part of a phase II, multi-centre, open-label,
parallel-group, randomised study to compare the effi-
cacy of selumetinib (AZD6244) versus temozolomide.
Locally advanced or metastatic NSCLC samples were
obtained as part of a double-blind, placebo-controlled,
parallel-group, multicentre, randomised, phase III study
(Iressa Survival Evaluation in Lung Cancer (ISEL)) trial
[17]. All patients provided written informed consent; the
trials were ethically approved and performed according
to principles of good clinical practice.
Sample processing
All samples underwent a haematoxylin and eosin
pathology review to confirm the presence of tumour in
the samples. The NSCLC samples were macro-dissected
by scraping only the tumour area that had been selected
b yap a t h o l o g i s t .N oe n r i c h m e n tb ym a c r o - d i s s e c t i o n
was performed on the melanoma samples. This was
because the planned primary analysis method was
ARMS and macro-dissection was thought unnecessary
due to the sensitivity of the method. Genomic DNA was
extracted from thin sections totalling 40 μmb yd i g e s -
tion in proteinase K for 48 h, boiling in 5% chelex,
phase-extracting in chloroform, ethanol-precipitating
and resuspending in 100 μl water [18]. This method
eliminated the need for a xylene de-waxing step, thus
reducing potential tissue loss. The same extraction
method was used for both sample sets.
NSCLC DNA samples were quantified by quantitative
PCR using primers and probes specific to alpha-1 anti-
trypsin: forward control primer AGGACACCGAGGAA-
GAGGACTT; reverse control primer GGAATCACCT
TCTGTCTTCATTT, control probe Cy5-CTGCLTPAZ-
GAGGGGAA-Elle (L = LNA (locked nucleic acid) mod-
ified C, P = LNA G, Z = LNA T). All primers and
probes were manufactured by Eurogenetec. The primers
were 0.1 μM and TaqMan probes at 0.5 μM. PCR was
performed at 95°C for 10 min, followed by 40 cycles of
94°C for 45 s, 60°C for 1 min and 72°C for 45 s in the
MX3000 (Stratagene). Data were collected at the 60°C
stage of the reaction. A dilution series of known
amounts of normal genomic DNA (Roche) was ampli-
fied in the same machine run and the MX3000 software
extrapolated the DNA concentration of the unknown
samples from the standard curve generated.
This method of quantification was used rather than
spectrophotometry as it only measures amplifiable DNA.
Only NSCLC samples with detectable amplifiable DNA
(>5 genomic copies/μl) were used for mutation analysis.
Extracted melanoma DNA was not quantified prior to
mutation analysis. Instead, the control reaction was used
to determine DNA extraction success concurrent with
the ARMS reactions. The assays were considered to have
failed when the control reaction fell below the limits of
detection. If the DNA was found to exceed the maximum
recommended DNA amount, it was diluted below 1000
genomic copies per reaction and re-analysed.
DNA was extracted from 171 melanoma samples
(158 were FF-PET and 13 were frozen) and 433 FF-PET
NSCLC samples.
ARMS analysis
Five microlitres of melanoma DNA diluted 1/5 in water
(Sigma) was added to each mutation assay containing
primers that specifically amplified either BRAF 1799T>A
(resulting in either V600E, V600K or V600D amino acid
changes depending on the presence of an additional
mutation at position 1798 or 1800) and NRAS 181C>A
and 182A>G (Q61R) mutations, and primers that
amplify an unrelated sequence, which acts as a control
for the presence of DNA. Brilliant Multiplex Q-PCR
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with bovine serum albumin (New England Biolabs) to
reduce the PCR inhibitory effects of melanin in the mel-
anoma samples. Assays were performed in duplicate.
The primer pairs and TaqMan probes were as follows:
BRAF ARMS primer AAAAATAGGTGATTTTGGTC-
TAGCTACATA, reverse primer TAGTTGAGACCTT-
CAATGACTTTCTAGTAA, probe VIC-AATCTCGA
TGGAGTGGGTCCCATCAGTTTGAACA-TAMRA;
NRAS Q61K ARMS primer GTTTGTTGGACATA
CTGGATACAGCTGGTA, reverse primer TTCCC
CATAAAGATTCAGAACACAAAGATC, probe Yakima
Yellow-ALATGAGGALAGGCGAAGGC-BHQ1; NRAS
Q61R ARMS primer AZALTGGATACAGLTGGACP,
reverse primer TTCCCCATAAAGATTCAGAACA-
CAAAGATC, probe Yakima Yellow-ALATGAGGA-
LAGGCGAAGGC-BHQ1, forward control primer AGG
ACACCGAGGAAGAGGACTT; reverse control primer
GGAATCACCTTCTGTCTTCATTT, control probe
Cy5-CTGCLTPAZGAGGGGAA-Elle (L = LNA (locked
nucleic acid) modified C, P = LNA G, Z = LNA T). All
primers and probes were manufactured by Eurogenetec.
All ARMS primer pairs were at a concentration of
1 μM, the control reaction primers were 0.1 μMa n d
TaqMan probes at 0.5 μM. PCR was performed at 95°C
for 10 min, followed by 40 cycles of 94°C for 45 s, 60°C
for 1 min and 72°C for 45 s in the MX3000 (Stratagene).
Data were collected at the 60°C stage of the reaction.
Cell line DNA admixtures containing the mutation of
interest in a normal DNA background (ranging from
100% mutant - 1% mutant in a normal background) was
amplified in the same machine runs to act as positive
controls and evaluate limit of detection and sensitivity.
A mutation positive result was only accepted if it was
present in independent PCRs generated from the same
DNA sample. Seven hundred nanograms of normal
genomic DNA was used as a negative control to assess
assay specificity. This amount of DNA was significantly
greater than typical DNA yields from FF-PET material.
Results were not designated positive unless the mutation
was detected before any non-specificity to control for
false positive results.
EGFR ARMS analyses were performed on the NSCLC
DNA samples by DxS (Manchester) [17].
DNA sequencing
BRAF and NRAS sequencing analysis were conducted on
melanoma DNA samples only. Five microlitres of tumour
DNA diluted 1/5 in water was added to triplicate PCR
assays containing PCR buffer II at 2 mM MgCl2,3 . 7 5
units AmpliTaqGOLD (ABI), 200 μMd N T P( A B g e n e )
and supplemented with bovine serum albumin (New
England Biolabs) with 5’ end tagged primers (forward
primer tag: ACTGTAAAACGA CGGCCAGT; reverse
primer tag: ACCAGGAAACAGCTATGACC) that
amplified BRAF exon 15, and NRAS exon 2: BRAF exon
15 forward TTTCCTTTACTTACTACACCTC, reverse
CTTTCTAGTAACTCAGCAGCATC; NRAS exon 2 for-
ward CCCCCAGGATTC TTACAGAA; reverse ATA-
CACAGAGGAAGCCTTCG. PCRs were conducted
using the following cycling conditions: 95°C, 10 min,
(94°C, 30 s, 58°C, 30 s, 72°C, 1 min) × 40 cycles, 72°C,
10 min.
EGFR analysis was conducted on NSCLC DNA sam-
ples. Five microlitres of tumour DNA diluted 1/5 in
water was added to triplicate PCR assays containing
PCR buffer II at 2 mM MgCl2,3 . 7 5u n i t sA m p l i T a q -
GOLD (ABI), 200 μM dNTP (ABgene) and supplemen-
ted with bovine serum albumin (New England Biolabs)
with 5’ end tagged primers (forward primer tag: ACTG-
TAAAACGACGGCCAGT; reverse primer tag: ACCAG-
GAAACAGCTATGACC) that amplified EGFR exons 18
to 21: EGFR exon 18 forward CCTTCCAAATGAGCT
GGCAAGTG, reverse TCTCACAGGACCACTGAT-
TACTG; EGFR exon 19 forward GCAGCATGTGG
CACCATCTCAC, reverse CAGGGTCTAGAGCAGAG-
CAGC; EGFR exon 20 forward CGCATTCATGCGTCT
TCACCTG, reverse CTATCCCAGGAGCGCAGACCG;
EGFR exon 21 forward TCGACGTGGAGAGGCTCA-
GAG and reverse CTGCGAGCTCACCCAGAATGTC.
PCRs were conducted using the flowing conditions:
95°C 10 min, (94°C, 20 s, 61°C, 30 s (dropping 0.5°C/
cycle), 72°C, 1 min) × 13 cycles, (94°C, 20 s, 57°C, 30 s,
72°C,1 min) × 30 cycles, 72°C, 10 min.
Resulting PCR products were bidirectionally
sequenced using primers complimentary to the Forward
and Reverse tags on the primary PCR primers using ABI
Big Dye sequencing, and analysed using Mutation Sur-
veyor software (SoftGenetics). To eliminate false positive
mutations occurring due to sample fixation artefacts, a
mutation result was only accepted if it was present in at
least two out of three independent PCRs in at least one
of each Forward and Reverse sequencing traces.
Results
Melanoma analysis
Out of the 177 melanoma samples extracted, 163 (92%)
were successfully analysed by ARMS as indicated by the
presence of the control reaction, and 156 (88%) were
successfully analysed by DNA sequencing as indicated
by readable sequencing traces.
In total, 69 BRAF mutations were detected using a
combination of both methods; 67 of these were at codon
600, one at codon 601 (K601E) and another at codon 581
(N581S). The 67 codon 600 mutations (1799T>A) were
detected using the ARMS assay but only 46 of these were
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V600E mutations and five were V600K. The BRAF
1799T>A ARMS assay could detect V600E, V600K and
V600D mutations as they all contain mutations at the
same nucleotide position, but could not distinguish
between them. The V600K and V600D amino acid
changes contain additional nucleotide substitutions,
although these do not affect the ARMS assay’s ability to
detect 1799T>A change. Ten samples were BRAF ARMS
mutation positive but the mutation was not seen in the
sequencing traces, demonstrating that ARMS was more
sensitive than DNA sequencing. No sequencing data
were obtained for 11 ARMS positive samples as they
failed to amplify or give readable sequencing traces. The
failure of DNA sequencing could in part be explained by
t h ed i f f e r e n c ei ns i z eo ft h eA R M SP C Rp r o d u c ta n dt h e
sequencing product that were 179 base pairs (bp) and
212 bp, respectively. The sequencing product was longer
to encompass the whole exon. There were no BRAF
1799T>A mutations detected by DNA sequencing that
were not detected by ARMS although DNA sequencing
revealed two mutations in different codons that could
not be detected by the ARMS assay. BRAF mutations
found in the melanoma samples using a combination of
DNA sequencing and ARMS are listed in Table 1.
In total, 28 NRAS mutations were detected using a
combination of both methods. Twelve were 182A>G
(Q61R), 15 were 181C>A (Q61K) and one 37G>C
(G13R). The G13R mutation was not detectable by the
specific ARMS assays used. Twenty-seven were detected
using the ARMS assay whereas only 21 (including the
G13R mutation) were detected by DNA sequencing. Of
the 27 ARMS mutation positive samples, three were
sequencing negative and four failed sequencing. The fail-
ure of DNA sequencing was not due to a size difference
between the ARMS PCR products (190 and 201 bp) and
the sequencing product (140 bp) as the sequencing pro-
duct was smaller in this case. There were no NRAS
181C>A and 182A>G 1799T>A mutations detected by
DNA sequencing that were not detected by ARMS.
NRAS mutations found in the melanoma samples
using a combination of DNA sequencing and ARMS are
listed in Table 2.
Performance on low-quality FF-PET DNA
All the frozen samples amplified well in both assays. 158
samples were FF-PET. Sixteen samples failed to generate
ARMS assay data (i.e. no control reaction detected) and
25 failed to generate sequencing data due to low DNA
amounts. Nine of these samples failed both sequencing
and ARMS, 7 samples failed ARMS only, and 16 sam-
ples failed sequencing only. Eleven samples that failed
sequencing were found to be BRAF ARMS positive.
These data indicate that ARMS is more successful at
genotyping samples in low quality FF-PET extracted
DNA. The results are summarised in Fig. 1A.
DNA quantity and ability to detect mutations
The first 121 of the melanoma samples yielding DNA
were grouped by DNA yield to determine if at low DNA
quantity the ability to detect mutations was reduced. The
groupings (>5 copies, 5-9 copies, 10-49 copies, 50-99
copies, 100-500 copies and >500 copies) were based on
the amount of DNA in the control reactions that could
be used to estimate the amount of DNA in the sample.
There were more groupings at the lower DNA concen-
tration as it was thought that any effect would be more
likely to be observed in these samples. There was no
decrease in the ability to detect mutations as the DNA
amount decreased. Both DNA sequencing and ARMS
gave similar results in each category although overall
ARMS detected more mutations. As the DNA concentra-
tion increased the number of successful sequencing reac-
tions also increased: at >50 copies per assay input, the
analysis success rate was very similar for both ARMS and
sequencing. The results are shown in Fig. 2.
In some samples at high DNA concentrations (>1000
copies assay input) non-specific signal did occur in the
ARMS. In these samples it was important to dilute
DNA below 1000 copies per assay input and repeat the
analysis. This only affected a minority of samples - most
samples in excess of this DNA limit did not exhibit any
non-specificity at all. Why this should occur in some
samples and not others is not known but adds to the
difficulty of analysing FF-PET DNA.
Non-small-cell lung cancer analysis
Of the 433 samples extracted, 215 yielded detectable
amounts of DNA greater than 5 copies/μl. This was
Table 1 BRAF mutations found in the melanoma samples
using a combination of DNA sequencing and ARMS
Mutation No. of
mutations
Detected by
ARMS
Detected by
sequencing
V600E, V600K
(1799T > A)
67 67 46
K601E 1 ND 1
N581S 1 ND 1
Total 69 67 48
ND, not detectable.
Table 2 NRAS mutations found in the melanoma samples
using a combination of DNA sequencing and ARMS
Mutation No. of
mutations
Detected by
ARMS
Detected by
sequencing
G13R 1 ND 1
Q61R 12 12 10
Q61K 15 15 10
Total 28 27 21
ND, not detectable.
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to the age of the samples and also no guidance on sam-
ple collection was given as mutation analysis was not
initially planned for these samples. We compared DNA
sequencing success rate to DNA amount of the first 100
samples into the NSCLC study that yielded detectable
DNA. We found that below 10 copies there was a 90%
failure rate to either amplify or generate readable
sequencing traces. Between 10 and 40 copies the success
rate was 25%. As the DNA concentration improved, the
success rate also improved. At this point we decided
only to analyse samples by sequencing that were greater
than 10 copies/μl, and performed a nested PCR to
improve the success rate on the 10-40 copies/μls a m -
ples. Eighteen of the 215 samples yielded very low DNA
amounts (5-10 genomic copies/μl). This was insufficient
for sequencing and these samples were only analysed by
ARMS. Of these 18 samples ,t w oa l s of a i l e dA R M S
analysis.
Twenty-six mutation-positive patients were identified
using both methods and the mutations detected are
described in Table 3. One patient was found to have
b o t ha ne x o n1 9d e l e t i o n( d e lL 7 4 7 - P 7 5 3i n sQ )b y
sequencing only and an L858R point mutation by
ARMS only.
Nine mutations were neither L858R nor del E746-
A750 and could only be detected by sequencing. Ten
mutations were detected by ARMS but not sequencing.
Of these, two were from the 18 samples not analysed by
sequencing due to low DNA yield and eight were in
samples which failed to sequence. The failure of DNA
sequencing could in part be explained by the difference
in size of the ARMS PCR products and the sequencing
products. Although the ARMS assay details were pro-
prietary it was believed that the PCR products were less
than 150 bp, whereas the sequencing products ranged
from 291-511 bp. When DNA sequence data were
obtained the mutation status matched that generated by
ARMS. The results are summarised in Fig. 1B.
Discussion
In this study ARMS has been found to be both more sen-
sitive and robust at detecting somatic mutations in clini-
cal material than DNA sequencing. There were no
examples where ARMS did not detect an assay-specific
mutation that was detected by DNA sequencing. There
were 42 mutations detected by ARMS that were not
detected by DNA sequencing either due to low quantity
or quality DNA causing assay fails or low mutant DNA
compared to normal DNA in the sample that was beyond
the detection limit of sequencing. They were not believed
to be false positive results as they were known mutations,
the results were reproducible and adequate controls were
analysed in parallel. There were 12 mutations detected by
sequencing that were not detected by ARMS because the
ARMS assays used were not designed to detect these
mutations, either because the mutations were rare (mela-
noma study) or ARMS assays had not yet been developed
to detect these mutations. However, using the larger
panel of ARMS assays now available the number of
mutations detected by ARMS would be significantly
increased with potentially only 1 mutation being missed
from this study.
Even though ARMS is the more sensitive technique, in
the NSCLC samples from which DNA sequence could
be obtained no mutations were detected by ARMS that
were not detected by sequencing. Mutations were only
missed by DNA sequencing due to assay fails owing to
the low amounts of poor quality, fragmented DNA
yielded from the samples. This probably reflected the
fact that these samples had been macro-dissected prior
A
ARMS
32
(18 not detected
by sequencing)
(14 sequencing fails)
(not detectable by
specific ARMS assays)
Sequencing
3 66
B
ARMS
10
(2 not tested
by sequencing)
(8 failed sequencing)
(not detectable by
specific ARMS assays)
DNA sequencing
9 8
Figure 1 (A) Melanoma mutations. Sixty-six BRAF or NRAS
mutations were detected in the melanoma samples by both
methods. ARMS detected an additional 32 mutations. Eighteen of
these were not detected on the sequencing traces and 14 failed to
sequence. Three mutations were detected by sequencing only.
These were mutations that the ARMS assays were not designed to
detect. (B) NSCLC mutations. Eight EGFR mutations were detected in
the NSCLC samples by both methods. ARMS detected an additional
10 mutations. Two of these were not analysed by sequencing as
the DNA amount was too low and eight failed to sequence. Nine
mutations were detected by sequencing only. These were
mutations that the ARMS assays were not designed to detect. Note
that there were 27 mutations in 26 patients as one sample was
found to contain two mutations.
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abundance of mutant DNA in the sample. However, the
macro-dissection process was very time-consuming and
labour-intensive and required specialist pathologist
input. Reducing the size of the PCR amplicons used in
sequencing may also have reduced the number of sam-
ples that failed in DNA sequencing.
In the melanoma study, no macro-dissection was per-
formed. This was because the planned primary analysis
method was ARMS and macro-dissection was thought
unnecessary due to the sensitivity of the method. The
results of the melanoma analysis reflected this as not all
mutations detected by ARMS were visible on sequen-
cing traces. They were not believed to be false positive
results as they were known mutations, the results were
reproducible and high levels of normal DNA was used
as a control for non-specificity.
As the analysis method for the melanoma study was
ARMS we did not quantify the DNA prior to analysis
because the ARMS assays contained a control reaction
that could be used to semi-quantify the DNA at the same
time as performing the diagnostic reaction. Eliminating
the quantification step reduced the analysis time. For the
NSCLC study, however, the primary method was sequen-
cing as there were only two EGFR mutant ARMS assays
available at the time of the study and while the common
mutations were well established, the number of rarer
mutations being discovered was still increasing.
To reduce the effort of sequencing in the many samples
(179 samples were >10 copies/μl [empirically determined
cut-off for sequencing]) that would have failed in 90% of
the cases and to reduce the costs of the commercial assays
we quantified the extracted DNA and only analysed the
samples where there was a good chance of success. For
NSCLC EGFR ARMS analysis we only analysed DNA
samples greater than five copies of DNA/5 μl( w i t h5μl
added to the PCR) as this was the limit of detection
claimed for these assays (218 samples were <5 copies/μl).
Interestingly, as the melanoma DNA yield decreased,
there was little drop-off in the percentage of BRAF or
NRAS mutations detected using either ARMS or
sequencing. This would suggest that even at low DNA
assay input the samples were representative of the
tumours and that at low DNA input there were prob-
ably few, if any, false negative results. Analysing all sam-
ples was a good strategy to maximise the numbers of
mutations detected in this study set where 88% of the
samples yielded detectable DNA.
In a research setting one of the strengths of sequen-
cing is that it detects unknown mutations as well as
known ones. However, in a clinical setting it is likely
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Figure 2 Mutation detection success on varying the amount of
input DNA. The DNA yield was grouped into categories and the
percentage of mutations detected calculated for each group. The n
values are the successful number of sequencing and ARMS analyses.
The lower yielding samples did not show any decrease in the
numbers of BRAF or NRAS mutations detected. Both DNA
sequencing and ARMS gave similar results in each category
although overall ARMS detected more mutations. As the DNA
concentration increased the number of successful sequencing
reactions also increased: at >50 copies per assay input, the analysis
success rate was very similar for both ARMS and sequencing.
Table 3 EGFR mutations found in the NSCLC samples using a combination of DNA sequencing and ARMS
Mutation No. of mutations Detected by ARMS* Detected by sequencing
del E746-A750 9 9 4
del E749-E758insQP 1 ND 1
del L747-P753 ins Q 1* ND 1
del E749-A753 ins P 1 ND 1
del L747-P753 ins S 1 ND 1
Other deletions 1 ND 1
G719A 1 ND 1
A743S 1 ND 1
L858R 9* 9 4
L861Q 2 ND 2
Total 27 18 17
EGFR-2 kit detecting L858R and del E746-A750 only. Other mutations not detectable by this version of the kit.
*One patient had both an exon 19 deletion and an L858R point mutation.ND, not detectable.
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acterised mutations. When analysing genes where muta-
tions are found clustered in one or two exons, like
KRAS, much less DNA is required for sequencing than
for ARMS, although this can be reduced by multiplexing
ARMS reactions. This can be an advantage when only
very small biopsies with low DNA are available. Sequen-
cing also offers an advantage when genes contain many
mutations throughout the coding region, such as p53,
BRCA and APC. To develop the potentially hundreds of
individual mutation detection assays required would be
extremely time-consuming and require positive muta-
tion controls to show that the assays are functioning
correctly. Sequencing reactions tend to be easier to
develop and standard genomic DNA is an adequate
control.
It was important when performing sequencing that at
least two independent PCRs were performed from the
original genomic DNA to eliminate false positive errors.
We were able to distinguish true mutations from arte-
factual mutations by only accepting mutations detected
in at least two amplicons in forward and reverse sequen-
cing directions. Approximately 2% of the exons
sequenced contained an artefact. These were most com-
monly detected in samples with low DNA, probably
because they were not masked by more abundant unal-
tered DNA. These artefacts are presumably caused by
damage to the DNA during fixation in formalin. None
of the artefacts found in singleton were known muta-
tions. They were not reproducible in any subsequent
PCR from the original DNA samples and we were
unable to validate them using other mutation discovery
methods including denaturing high-performance liquid
chromatography, and cloning and sequencing. ARMS
appeared to be less affected by DNA artefacts as the
assays only targeted known mutations. Pathology infor-
mation was also taken into account as this could often
explain why mutations were present at a low level in a
sample.
In contrast to the advantages of sequencing, the ARMS
assays were easy to perform and interpret and lend
themselves to better standardisation, which helps when
performing mutation analysis on a global scale or as a
companion diagnostic. As ARMS is very sensitive, routi-
nely being able to detect at least 1% mutant in a back-
ground of normal DNA, this may reduce the need for
macro-dissection which eliminates a labour-intensive,
time-consuming step in the analysis process. By coupling
ARMS with real-time PCR product detection the analysis
process is further shortened as PCR products do not
have to be processed, for example by agarose gel electro-
phoresis, and PCR product contamination is eliminated
as reaction tubes do not need to be opened after the
experiment is complete.
As ARMS is sensitive it can also be used on samples
where the tumour content is very low, for example cir-
culating free (cf) tumour DNA shed from the tumour
into the blood [19,20] and in cytology samples [21,22].
This can be an advantage when a tumour sample is not
available, for example if the tumour is inoperable or so
badly processed that no DNA is extractable. However,
in our experience, the mutation detection rates using
alternative sources of tumour such as cf DNA tend to
be lower than from a tumour biopsy.
In this study we have evaluated ARMS and DNA
sequencing only; however, there are a growing number
of alternative methods being established that may merit
evaluation. All methods have their own merits and are
chosen according to the task e.g. clinical trial methodol-
ogy may be different to those employed in the diagnos-
tic setting for sensitivity, cost, availability and a variety
of other reasons. Test choice will differ as tests evolve
and it is important to keep abreast of all available
methods.
In our experience, ARMS is more sensitive and robust
at detecting defined somatic mutations than DNA
sequencing on clinical samples where the predominant
sample type was FF-PET. Future developments in the
field of mutation detection will be followed with antici-
pation as such technologies will be key to support per-
sonalised healthcare approaches that select patients for
targeted treatments based on tumour mutation results.
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